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ABSTRACT 
Background 
Omega-3 fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] are 
widely recommended for health promotion. Over the last decade, prescription omega-3 fatty 
acid products (RxOME3FAs) have been approved for medical indications. Nonetheless, there 
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is no comprehensive analysis of safety and tolerability of RxOME3FAs so far.  
 
Methods 
A systematic review of randomized controlled trials (RCTs) was carried out based on 
searches in six electronic databases. The studies involving marketed RxOME3FA products 
were included, and adverse-effect data were extracted for meta-analysis. Subgroup analysis 
and meta-regression were conducted to explore the sources of potential heterogeneity. 
 
Results 
Among the 21 included RCTs (total 24,460 participants; 12,750 from RxOME3FA treatment 
cohort and 11,710 from control cohort), there was no definite evidence of any 
RxOME3FA-emerging serious adverse event. Compared with the control group, 
RxOME3FAs were associated with more treatment-related dysgeusia (fishy taste; p = 0.011) 
and skin abnormalities (eruption, itching, exanthema, or eczema; p < 0.001). Besides, 
RxOME3FAs had mild adverse effects upon some non-lipid laboratory measurements 
[elevated fasting blood sugar (p = 0.005); elevated alanine transaminase (p = 0.022); elevated 
blood urea nitrogen (p = 0.047); decreased hemoglobin (p = 0.002); decreased hematocrit (p 
= 0.009)]. Subgroup analysis revealed that EPA/DHA combination products were associated 
with more treatment-related gastrointestinal adverse events [eructation (belching; p = 0.010); 
nausea (p = 0.044)] and low-density lipoprotein cholesterol elevation (p = 0.009; difference 
in means = 4.106 mg/dL). 
 
Conclusion 
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RxOME3FAs are generally safe and well tolerated but not free of adverse effects. 
Post-marketing surveillance and observational studies are still necessary to identify long-term 
adverse effects and to confirm the safety and tolerability profiles of RxOME3FAs. 
 
Keywords:  
omega-3 fatty acid; prescription; adverse effect; adverse event; safety; tolerability 
 
1. Introduction 
Omega-3 fatty acids (OME3FAs), especially eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are essential nutrients for humans and are promising 
nutraceuticals [1]. There has been much evidence showing their benefits for not only various 
physical conditions[2-9] but also several mental disorders [10-16]. Nowadays, the 
supplementation with OME3FAs or fish oil products has become increasingly popular 
worldwide. However, dietary supplements are usually loosely regulated as compared to 
prescription drugs. Supplements do not have to meet strict government regulatory standards 
on purity, quality, efficacy, and safety as pharmaceutical agents do. As a result, fish oil dietary 
supplements on the market may contain uncertain concentrations of OME3FAs and possibly 
saturated fat or other contaminants [17, 18].  
Over the last decade, prescription omega-3 fatty acids (RxOME3FAs) have been available 
in many countries. Oral RxOME3FAs are indicated as an adjuvant therapy in adult patients 
for secondary prevention of post-myocardial infarction and the treatment of 
hypertriglyceridemia in European countries and for the treatment of hypertriglyceridemia 
(serum triglyceride levels ≥ 500 mg/dL) in the US [19]. 
RxOM3FAs appear to have favorable safety and tolerability profiles [20, 21]. Unlike 
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other triglyceride-lowering therapies, such as niacin or fenofibrate, RxOM3FAs have not been 
associated with risk of rhabdomyolysis when taken alone or in combination with statins [22]. 
However, according to the Micromedex® database, there are still some safety concerns, 
especially regarding hypersensitivity (e.g., “use with caution in patients with known 
hypersensitivity to fish and/or shellfish”), the risk of bleeding, elevated low-density lipoprotein 
(LDL) cholesterol, increased alanine transaminase (ALT) or aspartate transaminase (AST), and the 
risk of recurrent atrial fibrillation/flutter [23]. Concurrent use of RxOM3FAs and anticoagulants 
or antiplatelet agents may increase the risk of bleeding [23]. On the other hand, recent 
evidence suggests that the bleeding risk is more modest than originally hypothesized [24, 25] 
and there is also evidence against the association between OME3FAs and atrial 
fibrillation/flutter [26]. 
There are two subgroups of RxOME3FA preparations available on the worldwide market: 
EPA/DHA combinations and EPA-only products [21]. In the US, most of the approved 
RxOME3FA products are EPA/DHA combinations, including Lovaza® (“omega-3-acid ethyl 
ester”), Omtryg® (“omega-3-acid ethyl ester A”), and Epanova® (“omega-3-carboxylic 
acid”). The EPA-only product, Vascepa® (“icosapent ethyl”), is the only single-compound 
formulation in the US [20]. In other countries, there are some other RxOME3FA products, 
such as Omacor®(“omega-3-acid ethyl ester 90”), Lotriga®(“omega-3-acid ethyl ester”), and 
Epadel®(“ethyl icosapentate”). In Japan, Epadel is approved for the treatment of 
hyperlipidemia as well as for alleviation of ulcer, pain, and cold feeling associated with 
arteriosclerosis obliterans [27]. (see Supplementary Table S1 for the overview of RxOME3FA 
products). 
Based on the prescribing information on RxOME3FAs, it has been suggested that these two 
subgroups may have different adverse-effect profiles [20, 27]. For the combination products, 
gastrointestinal complaints, e.g., eructation, dyspepsia, and taste perversion, are the most 
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commonly reported adverse events (AEs) (incidence >3% and greater than placebo). For 
EPA-only products, arthralgia is the only adverse event (AE) occurring at an incidence >2% and 
more frequently than placebo [20, 27]. Warnings about LDL elevation have been mentioned in 
the labeling of DHA-containing products but not EPA-only preparations [23]. 
Given these uncertainties and controversies, the aim of this systematic review and 
meta-analysis was to comprehensively assess the literature on randomized controlled trials 
(RCTs) to investigate the potential for AEs and laboratory abnormalities associated with 
marketed RxOME3FAs. In addition, the differences between EPA/DHA combinations and 
EPA-only products were explored as well. 
 
2. Methods 
2.1 Protocol 
The present study followed the guidelines of Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) [28]. The current meta-analysis fulfilled the 
certification requirements of the Institutional Review Board of the Kaohsiung Veterans 
General Hospital (approval # VGHKS17-EM10-01). 
 
2.2 Literature search and screening 
To focus our search results on marketed RxOME3FAs, we used the following search string: 
“omega-3-acid ethyl ester” OR “omega-3-acid ethyl ester 90” OR “omega-3-acid ethyl ester 
A” OR “omega-3-carboxylic acid” OR “icosapent ethyl” OR “ethyl icosapentate” OR 
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“lovaza” OR “omacor” OR “lotriga” OR “epanova” OR “omtryg” OR “vascepa” OR “epadel” 
without specific limit on the languages . The above search terms covered major generic and 
brand names of RxOME3FAs not only in the US but also in Asian and European countries 
[29]. 
To identify eligible studies, we searched databases for studies available by September 17, 
2017 (electronic databases PubMed, EMBASE, ProQuest, ScienceDirect, Cochrane Central 
Register of Controlled Trials, and ClinicalTrials.gov). In addition, to expand the list of 
potential eligible references, we performed manual searches for references found in relevant 
articles and package inserts. 
The titles and abstracts of studies retrieved by the search strategy were screened by two 
review authors (CH Chang and NY Chen) to determine whether the studies were potentially 
eligible for inclusion in this meta-analysis. In case of disagreement on eligibility, we reached 
an agreement through consensus. 
 
2.3 Study selection and quality appraisal 
All the studies included in this analysis had to meet the following inclusion criteria: (1) 
RCTs that compared the adverse effect of RxOME3FAs versus controls, either in the form of 
a placebo, other medication, or “no treatment”; (2) human subjects in the trials. To include as 
many eligible studies as possible, we did not set a limit on the diseases in articles and we did 
not set a limit on the languages. Studies that were apparently noneligible were excluded in 
case of exclusion criteria: (1) review articles, (2) animal studies, (3) non-RCT trials, (4) 
topics not related to the adverse effects of marketed RxOME3FA products, and (5) dietary 
supplements. We used the Jadad scale to evaluate the quality of each included study [30]. 
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2.4 Data extraction and correspondence with the authors 
Using a predetermined list of data forms of interest, two review authors (CH Chang and 
NY Chen) independently evaluated the selected studies for review. The data extraction form 
included a description of the types of participants, the type, dose, and duration of marketed 
RxOME3FAs, as well as AEs, serious adverse events (SAEs), and laboratory measurements 
for each of the reviewed studies. When needed, an email addressed to the corresponding 
author was sent requesting unpublished data. In the present study, we examined the safety 
and tolerability profiles of RxOME3FAs through the systematic review and meta-analysis of 
SAEs (safety), AEs (tolerability) and laboratory measurements (safety and tolerability). SAEs 
were defined as AEs that resulted in death, a life-threatening condition, inpatient 
hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth 
defect, or a condition that requires further intervention to prevent one of the consequences 
mentioned above [31]. 
 
2.5 Methods of meta-analysis 
In the present study, the meta-analytic procedures consisted of two parts: (a) analysis of 
dichotomous outcomes: differences in treatment-related AEs, and (b) analysis of continuous 
outcomes: differences in treatment-related laboratory findings. 
Due to anticipated heterogeneity, all the effect measures were synthesized using a 
random-effects model rather than a fixed-effects meta-analysis because random-effects 
modeling is more stringent in terms of inclusion of among-study variance [32]. Under the 
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preliminary assumption that the units of measurement of target laboratory data are 
heterogeneous among the recruited studies, we chose Hedges’ g and 95% confidence intervals 
(CIs) to combine the effect sizes for continuous items, according to the manual of the 
Comprehensive Meta-Analysis ver. 3 software. Hedges’ g greater than 0 indicated a 
significantly worse effect of RxOME3FAs. In the case of the same units for measuring target 
continuous laboratory variables, we also used differences in means as effect sizes, which can 
be defined as “values after RxOME3FAs treatment minus values before RxOME3FAs 
treatment.” For dichotomous outcomes, the summary of effect sizes was defined as the odds 
ratio (OR). An OR greater than 1 indicated significantly more AEs of RxOME3FAs. 
The meta-analytic procedures were performed in the Comprehensive Meta-Analysis 
software, version 3 (CMA ver. 3.0; Biostat, Englewood, NJ). A two-tailed p value of less than 
0.05 was assumed to indicate statistical significance. 
 
2.6 Heterogeneity, publication bias, and sensitivity test 
The heterogeneity test had been investigated using Q statistics and the corresponding p 
values [33]. The I
2
 statistics indicated the proportion of variation among the recruited studies 
[34]. Two steps of investigation of potential publication bias had been applied. At first, if 
there had been fewer than 10 datasets, we applied the funnel plot to investigate publication 
bias [35]; one the other hand, in the case of ≥10 datasets, we chose Egger’s regression to 
investigate it [36]. When there was evidence of publication bias, we performed Duval and 
Tweedie’s trim-and-fill test to adjust the effect sizes for potential publication bias [37]. 
Furthermore, to evaluate the potential confounding effect of any outlier within the included 
studies, we conducted a sensitivity test by the one-study removal method, which has been 
widely used in meta-analyses, to detect the potential outliers. In brief, we removed one study 
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at a time and reanalyzed the results of meta-analysis to see if there was any change in the 
results of the meta-analysis. If the results of the meta-analysis changed, then, that study might 
be the outlier or had a larger sample size [38]. 
 
2.7 Meta-regression and subgroup analysis 
To investigate potential sources of heterogeneity, meta-regression was carried out by the 
unrestricted maximum likelihood method in case of at least five datasets. Furthermore, to find 
the differences between EPA/DHA combinations and EPA-only products, a subgroup analysis 
was performed when at least three articles were included [39]. 
 
3. Results 
3.1 Systematic review and the selection process 
The full search strategy is illustrated in Figure 1. We examined the full text of the 
remaining 49 articles, and 26 of them were found to be ineligible because there was no report 
of adverse effects and the articles did not meet the inclusion criteria for the meta-analysis. 
Among the remaining 23 articles, two studies were excluded because we could not extract 
specific adverse-effect data from the articles or obtain the unpublished data from the 
corresponding authors [40, 41]. Thus, the remaining 21 articles were included in the present 
meta-analysis [42-62]. The characteristics of the included studies are described in Table 1.  
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3.2 Description and quality assessment of the included studies 
The included studies originated from the United States (n = 13), the United Kingdom (n = 
2), the Netherlands (n = 1), Norway (n = 1), Japan (n = 3), and Taiwan (n = 1). All the trials 
were published between 1997 and 2017. The total number of participants in all reviewed 
studies was 24,460 (12,750 from RxOME3FA treatment cohort and 11,710 from control 
cohort) with a reported mean age of 54.642 years. The duration of trials ranged from 6 to 96 
weeks. 
Among the 21 included RCTs, four used EPA-only products, and the other 17 studies 
involved EPA/DHA combinations. Sixteen of them were RxOM3FA-alone, and the other five 
were add-on-statin studies [47-51]. In terms of the characteristics of recruited subjects, there 
were 15 studies for dyslipidemia, three studies on cardiovascular diseases, one study on 
postmenopausal healthy women, one study on type 2 diabetes mellitus, and one study on 
Huntington disease. 
 
3.3 Methodological quality of the included studies 
The details of methodological quality assessment of the included studies are provided in 
Table 1. Across the included studies, the mean Jadad score was 3.71 with a standard deviation 
(SD) of 1.10. 
 
3.4 Review of the SAEs 
Among the 21 included studies, there were some reports of SAEs, not only in the 
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RxOME3FA-treated arm but also in the control arm [43, 46-48, 50, 52, 54, 56, 57, 59, 60, 62]. 
None was considered by the investigators to be associated with RxOME3FAs. Only an 
incident of myelofibrosis in a patient receiving Lotriga (TAK-085; 2 g/day) was regarded as 
having a possible relation with the study drug by the authors [56]. 
 
3.5 Main results of the meta-analysis of the prevalence rates of AEs (dichotomous items) 
Among the included studies, the prevalence rates of AEs were successfully extracted from 
20. The detailed results on the meta-analysis of prevalence rates of AEs among the 
participants taking RxOME3FAs and the rates among controls are listed in Table 2A. In brief, 
there were significantly higher prevalence rates only for “dysgeusia” (OR = 4.229, 95% CI = 
1.399 to 12.780, p = 0.011) and “skin rash” (OR = 2.461, 95% CI = 1.869 to 3.242, p < 0.001) 
among participants taking RxOME3FAs than among the controls.  
 
3.5.1 Sensitivity test 
The main results of the meta-analysis did not change after removal of any one of the 
included studies except for the situations listed below. The significant result of meta-analysis 
of the prevalence rate of skin rash changed to “insignificant” after removal of the dataset of 
Yokoyama et al. (2007) [48]. The insignificant result in meta-analysis of the prevalence rate 
of constipation changed to “significant” after removal of the dataset of Kowey et al. (2010) 
[52]. The insignificant result from the meta-analysis of prevalence rates of myalgia changed 
to “significant” after removal of the dataset of Holman et al. (2009)[49] or removal of the 
dataset on 4000 mg/day OME3FAs (Tatsuno et al., 2013) [57]. The significant results from 
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the meta-analysis of the prevalence rate of dysgeusia changed to insignificant after removal 
of the dataset of Heydari et al. (2016) [60].  
 
3.5.2 Meta-regression 
The main results of meta-regression are listed in Supplement Table S2A.  
 
3.5.3 Subgroup analysis 
We performed subgroup analysis and the results are listed in Table 3A.  
 
If we focused on those trials with EPA/DHA combination products, then there was a 
significantly higher prevalence rate of eructation and nausea among the participants taking 
combination products than among controls. As for EPA-only products, there was no 
significant finding. Meta-analysis was performed on arthralgia and showed no significant 
differences between the participants taking EPA-only products and controls. 
 
3.6 Main results on laboratory adverse effects on lipid profiles (continuous items) 
Among the included studies, lipid profiles were successfully extracted from 11. The 
detailed results of meta-analysis of adverse effects on laboratory measurements among the 
participants taking RxOME3FAs and among controls are listed in Table 2B.  
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In brief, there was harmful effect on low-density lipoprotein (LDL; k = 13, Hedges’ g = 
0.208, 95% CI = 0.052 to 0.364, p = 0.009; difference in means = 4.106 mg/dL, 95% CI = 
1.349 to 6.863), but beneficial effect on non-high-density lipoprotein (non-HDL) (k = 7, 
Hedges’ g = -0.214, 95% CI = -0.382 to -0.045, p = 0.013; difference in means = -5.317 
mg/dL, 95% CI = -9.521 to -1.112), total cholesterol (T-Cho; k = 12, Hedges’ g = -0.136, 
95% CI = -0.264 to -0.007, p = 0.039; difference in means = -3.792 mg/dL, 95% CI = -7.715 
to 0.130), triglyceride (TG; k = 11, Hedges’ g = -0.474, 95% CI = -0.693 to -0.255, p < 0.001; 
difference in means = -39.692 mg/dL, 95% CI = -61.164 to 18.220), and very low-density 
lipoprotein (VLDL; k = 5, Hedges’ g = -0.499, 95% CI = -0.856 to -0.143, p = 0.006; 
difference in means = -7.048 mg/dL, 95% CI = -13.190 to -0.905) among the participants 
taking RxOME3FAs in comparison with controls. 
 
3.6.1 Sensitivity test 
The main results of meta-analysis did not change after removal of any one of the included 
studies except for the situation listed below. Only the significant result of meta-analysis of 
differences in adverse effects on non-HDL and T-Cho changed to “insignificant” after 
removal of some included datasets; this phenomenon might be due to the smaller sample 
sizes after removal of those datasets. 
 
3.6.2 Meta-regression 
The main results of meta-regression are listed in Supplement Table S2B.  
 
 14 
3.6.3 Subgroup analysis 
We carried out subgroup analysis and the results are listed in Table 3B.  
 
In brief, most of the results of subgroup analysis did not change for some combination 
products. Nevertheless, we did not perform subgroup analysis on some EPA-only products 
because there were fewer than three datasets. 
 
3.7 Main results on laboratory adverse effects on non-lipid profiles (continuous items) 
Among the included studies, non-lipid laboratory measurements were successfully 
extracted from 5. The detailed results are listed in Table 2B. In brief, there were significantly 
worse effects on fasting blood sugar (Fasting sugar or AC sugar; k = 8, Hedges’ g = 0.121, 
95% CI = 0.036 to 0.206, p = 0.005; difference in means = 3.750 mg/dL, 95% CI = 0.921 to 
6.579), alanine transaminase (ALT; k = 8, Hedges’ g = 0.099, 95% CI = 0.014 to 0.184, p = 
0.022; difference in means = 1.856 U/L, 95% CI = 0.270 to 3.443), blood urea nitrogen (BUN; 
k = 5, Hedges’ g = 0.132, 95% CI = 0.002 to 0.263, p = 0.047; difference in means = 0.595 
mg/dL, 95% CI = -0.221 to 1.411), hemoglobin (Hb; k = 6, Hedges’ g = 0.204, 95% CI = 
0.075 to 0.334, p = 0.002; difference in means = -0.280 g/dL, 95% CI = 0.095 to 0.464), and 
hematocrit (Hct; k = 6, Hedges’ g = 0.173, 95% CI = 0.043 to 0.302, p = 0.009; difference in 
means = -0.639%, 95% CI = 0.152 to 1.127) without significant heterogeneity (Q = 1.810, df 
= 5, I
2
 < 0.001%, p = 0.875) among participants taking RxOM3FAs relative to controls. 
In contrast, there were beneficial effects on alkaline phosphatase (ALP; k = 5, Hedges’ g 
= -0.206, 95% CI = -0.335 to -0.076, p = 0.002; difference in means = -4.169 U/L, 95% CI = 
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-7.260 to -1.077) and platelets (Plt; k = 6, Hedges’ g = -0.170, 95% CI = -0.299 to -0.041, p = 
0.010; difference in means = 9.167 1000/µL, 95% CI = -16.215 to -2.120) among the 
participants taking RxOM3FAs than among the controls. 
 
3.7.1 Sensitivity test 
The main results of meta-analysis did not change after removal of any one of the included 
studies except for the situation listed below. Only the significant result of meta-analysis of 
differences in adverse effects on ALP, ALT, BUN, and Plt changed to “insignificant” after 
removal of some of the included datasets; this phenomenon might be due to a smaller sample 
size after removal of those datasets. 
 
3.7.2 Meta-regression 
The main results of meta-regression are listed in Supplement Table S2B.  
 
3.7.3 Subgroup analysis 
The main results are listed in Table 3B. If we focused on the trials with EPA/DHA 
combination products, then there was a significantly worse effect on Creatine kinase (CK) 
among the participants taking combination products than among controls. Nonetheless, the 
significance of the adverse effects on fasting blood sugar and ALT changed to insignificance 
in the subgroup analysis of combination products. In addition, because there were fewer than 
three datasets, the subgroup analysis was not performed on EPA-only products.  
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4. Discussion  
To our knowledge, this is the first systematic review and meta-analysis of the safety and 
tolerability of RxOME3FAs. To avoid inclusion of studies involving dietary supplements, we 
focused on specific generic and brand names rather than common terms like EPA, DHA, or 
omega-3 fatty acids. The comprehensive search strategy in the six electronic databases 
enabled more specific identification and synthesis of all available and eligible studies so far. 
Among the included studies (duration from 6 to 96 weeks), either RxOM3FA-alone or 
add-on-statin studies, there was no report of definitely RxOME3FA-related SAE.  
Concerning non-serious adverse effects, our findings comprised three parts: (1) 
treatment-related AEs; (2) treatment-related adverse effects on lipid profiles; (3) 
treatment-related adverse effects on non-lipid profiles.  
 
4.1 Treatment-related AEs  
To enhance the comparability and comprehensibility of terminology, we classified AEs 
based on the Medical Dictionary for Regulatory Activities (MedDRA) with some minor 
modifications [63, 64]. 
 
The main findings are that “dysgeusia” and (skin) “rash” are more prevalent among 
patients taking RxOME3FAs than among controls. 
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“Dysgeusia” is a MedDRA-preferred term, which means a “fishy taste” or “taste 
alteration” in the context of RxOME3FA treatment. This makes sense considering that most 
of the RxOME3FA products are made from fish oil extracted from fatty fishes. We classified 
this adverse effect into "gastrointestinal disorders" because the fishy taste is most likely due 
to gastrointestinal regurgitation without neurological mechanisms involved. Subgroup 
analysis of combination products revealed a higher prevalence rate of eructation (belching) 
and nausea in comparison with the controls. This finding is in line with the product labeling 
saying that the combination RxOME3FAs may cause gastrointestinal AEs. The other main 
finding, “rash,” is also a MedDRA-preferred term, and was statistically significant because of 
the (outlier) dataset of Yokoyama et al. (2007) [48] (relative weight 90.44%, see Figure 3A). 
Nonetheless, Yokoyama et al. did not use MedDRA terminology and reported “skin 
abnormalities” including heterogeneous conditions of not only eruption and exanthema but 
also itching and eczema [48]. Therefore, it is difficult to clarify the nature and underlying 
mechanism of this finding.  
Meta-analysis was also performed on “arthralgia” and yielded a nonsignificant result for 
RxOME3FAs overall (Table 2A) and for EPA-only products in subgroup analysis (Table 3A). 
According to the package insert of Vascepa (icosapent ethyl), arthralgia is the only AE 
occurring at an incidence >2.0% and more frequently than placebo, but in the present 
meta-analysis, the data from Yokoyama et al. (2007) [48] may have diminished this relation 
(Figure 3B). In this add-on-statin trial, patients in the control arm had more adverse events of 
“pain” (joint pain, lumbar pain, muscle pain) as compared with the EPA arm (2.0% versus 
1.6%). 
 
4.2 Treatment-related adverse effects on lipid profiles 
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The meta-analytic results on lipid profiles revealed a significantly beneficial effect of 
RxOME3FAs on TG, non-HDL, T-Cho, and VLDL. Among these findings, the effect on TG 
was the most robust, which is reasonable considering the official indication of RxOME3FAs.  
 
In terms of adverse effects, RxOME3FAs had small but significant harmful effect upon 
LDL (Hedges’ g = 0.208, 95% CI = 0.052 to 0.364, p = 0.009; difference in means = 4.106 
mg/dL, 95% CI = 1.349 to 6.863). It is our understanding that statins may reduce LDL by as 
much as 20% to 60% [65] and may mask the effect of RxOME3FAs on LDL in the present 
study. The meta-analytic result can become more significant after removal of the 
add-on-statin study (Davidson et al. 2007) [47] (Hedges’ g = 0.239, 95% CI = 0.065 to 0.413, 
p = 0.007; difference in means = 4.563, 95% CI = 1.627 to 7.499). The included datasets here 
were exclusively from trials involving combination products. On the contrary, the original 
studies on EPA-only preparations revealed no significant LDL differences as compared with 
the control groups [48, 54, 55]. 
The different effects of EPA and DHA on lipid profiles were explored in a recent 
meta-analysis of RCTs, which showed that although EPA and DHA both reduce TG levels, 
they have divergent effects on LDL and HDL [66]. It is proposed that DHA-containing 
formulations are associated with more significant increases in LDL and HDL than EPA-only 
therapies are [67]. Further research is needed to elucidate the significance and mechanisms 
underlying these differences. 
 
4.3 Treatment-related adverse effects on non-lipid profiles 
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The meta-analytic results on non-lipid laboratory tests (Table 2B) showed that 
RxOME3FAs may have an adverse effect on Fasting sugar (Hedges’ g = 0.121, 95% CI = 
0.036 to 0.206, p = 0.005), ALT (Hedges’ g = 0.099, 95% CI = 0.014 to 0.184, p = 0.022), 
BUN (Hedges’ g = 0.132, 95% CI = 0.002 to 0.263, p = 0.047), Hb (Hedges’ g = 0.204, 95% 
CI = 0.075 to 0.334, p = 0.002), or Hct (Hedges’ g = 0.173, 95% CI = 0.043 to 0.302, p = 
0.009). The mean differences were all relatively small and may have little or no clinical 
importance (i.e., difference in means were Fasting sugar = 3.750, ALT = 1.856, BUN = 0.595, 
Hb = -0.280, and Hct = -0.639). In fact, among the original studies, there were few reports of 
treatment-related non-lipid laboratory abnormalities, except for some reports of mild 
elevation of liver enzymes[47-49, 53]. Further clinical trials and observational studies are 
needed to clarify and confirm these findings, especially in the general population and patients 
with other comorbidities. 
  
4.4 Limitations 
There are several limitations of the present meta-analysis. First, because the underlying 
diseases might potentially affect the side effect profiles, the generalizability of our findings 
may be limited by the disease groups in our included RCTs (mostly for patients with 
metabolic or cardiovascular diseases). The safety and tolerability profiles may be different in 
other populations such as the general population, or patients with other comorbidities. Second, 
although we have contacted all the authors regarding unpublished data, there was still a lack 
of extractable and analyzable data for many target outcomes of interest, especially in 
subgroup analyses. Regarding concerns about the risk of bleeding and recurrent atrial 
fibrillation/flutter, these cannot be addressed by the present study owing to the lack of 
adequate data, either binary or continuous, for the meta-analysis. The safety of concurrent use 
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of RxOME3FAs and anticoagulants or antiplatelet agents is also beyond the scope of the 
present study. Third, there was a significant publication bias among our findings, including 
the results on dysgeusia, rash, arthralgia, and LDL. Although we performed an adjustment for 
the publication bias (see Table 2A & 2B), this adjustment may still leave some potential bias 
in our findings. Forth, as the limitation of meta-analysis, we could not directly adjust the 
potential confounding factors during the analytic procedure, such as mean dosage of 
RxOME3FAs. To overcome this limitation, we arranged meta-regression to investigate the 
potential correlation between effect sizes and mean dosage of RxOME3FAs (Supplement 
table S2A and S2B). Overall, we did not observe significant correlations between 
RxOME3FAs dosage and effect sizes of any clinical variables. 
There is considerable debate as to the relative merits of using RCT data as opposed to 
observational data in systematic reviews of adverse effects. In theory, well-conducted RCTs 
yield unbiased estimates of treatment and adverse effects. In reality, RCTs are usually 
designed and powered to explore efficacy and involve a relatively small number of 
participants who have been selected for the research purposes [68]. As a meta-analysis of 
RCTs, the current study may not be able to identify rare or long-term adverse effects and 
cannot replace observational studies, especially post-marketing surveillance. 
 
5. Conclusion 
RxOME3FAs are generally safe and well tolerated but not free of adverse effects. The 
present study showed that these products are associated with some non-serious adverse events 
and mild laboratory abnormalities. Post-marketing surveillance and observational studies are 
necessary to identify rare, long-term adverse effects and to refine and confirm the safety and 
tolerability profiles of RxOME3FAs. 
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Figure captions: 
Figure 1. Flowchart of the selection strategy and inclusion/exclusion criteria for the present 
meta-analysis. 
 
Figure 2. Forest plots showing the pooled effect sizes [odds ratio (OR) in panel A and 
Hedges’ g in panel B] and 95% confidence intervals (CIs) comparing patients treated and not 
treated with RxOME3FAs. (A): RxOME3FAs were associated with significantly greater 
prevalence rates of dysgeusia (p = 0.011) and skin rash (p < 0.001). (B): RxOME3FAs were 
associated with significantly more adverse effects upon Fasting sugar (p = 0.005), ALT (p = 
0.022), BUN (p = 0.047), Hb (p = 0.002), Hct (p = 0.009), and LDL (p = 0.009). In contrast, 
RxOME3FAs were also associated with significantly more beneficial effects upon ALP (p = 
0.002), Plt (p = 0.010), VLDL (p = 0.006), TG (p < 0.001), T-Cho (p = 0.039), and non-HDL 
(p = 0.013). 
 
Figure 3. Forest plots showing the effect sizes [odds ratio (OR) in panels A and B and 
Hedges’ g in panel C] and 95% confidence intervals (CIs) from individual studies and pooled 
results of the included studies. (A): individual studies and pooled results of dysgeusia (p = 
0.011) and skin rash (p < 0.001). (B): individual studies and pooled results of arthralgia in the 
subgroup analyses of EPA/DHA combination products (p = 0.768) and EPA-only products (p 
= 0.329). (C): individual studies and pooled results of LDL in the subgroup analysis of 
EPA/DHA combination products (p = 0.009; difference in means = 4.106 mg/dL).  
 
Table 1: Characteristics of the included studies 
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Author, 
year 
Country 
Population
s 
Study 
desig
n 
Comparis
on 
Subjec
ts 
Mean 
age 
(mean±S
D) 
Duratio
n 
(weeks
) 
Total 
Jada
d 
scor
e 
Extract
ed 
data* 
Harris, 
1997 
USA 
Dyslipide
mia 
patient 
DB-RC
T 
Omacor 4 
g/day 
Corn oil 
22 
20 
46.0±11.
0 
45.0±9.0 
16.0 3 
(2), (3) 
Borthwick, 
1998 
UK 
Dyslipide
mia 
patient 
DB-RC
T 
Omacor 4 
g/day 
Corn oil 
29 
26 
54.1±9.2 
52.8±9.2 
22.0 3 
(1), (2) 
Johansen, 
1999 
Norway 
PTCA 
patient 
DB-RC
T 
Omacor 4 
g/day 
Corn oil 
196 
192 
60.3±9.3 
59.1±9.3 
24.0 3 
(1), (2) 
van Dam, 
2001 
Netherlan
ds 
Dyslipide
mia 
patient 
DB-RC
T 
Omacor 4 
g/d 
Gemifibro
zil 
45 
44 
49.7 
50.1 
12.0 4 
(1) 
Puri, 2005 UK HD patient 
DB-RC
T 
Vascepa 
2g/d 
Placebo 
67 
68 
50.0±9.3 
49.0±9.0 
48.0 5 
(1) 
Davidson, 
2007 
USA  
Dyslipide
mia 
patient 
DB-RC
T 
Simvastati
n + Lovaza 
4 g/day 
Simvastati
n + 
vegetable 
oil 
capsules 
122 
132 
60.3±10.
1 
59.3±10.
8 
8.0 4 
(1), (2) 
Yokoyama, 
2007 
Japan 
Dyslipide
mia 
patient 
SB-RC
T 
EPADEL 
1.8 g/day 
+ statin 
Statin 
9326 
9319 
61.0±8.0 
61.0±9.0 
260.9 3 
(1) 
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Maki, 2008 USA 
Dyslipide
mia 
patient 
DB-RC
T 
Simvastati
n + Lovaza 
4 g/day 
Simvastati
n + 
vegetable 
oils 
39 
39 
60.3±10.
1 
59.3±10.
8 
 
 6.0 2 
(1) 
Holman, 
2009 
USA 
Type 2 DM 
patient 
DB-RC
T 
Atorvastat
in + 
omacor 2 
g/d 
Omacor 2 
g/d + 
olive oil 
Atorvastat
in + olive 
oil 2 g/d 
Olive oil + 
olive oil 
200 
197 
201 
202 
63.0 
64.0 
64.0 
65.0 
16.0 5 
(1) 
Maki, 2009 USA 
Dyslipide
mia 
patient 
DB-RC
T 
Lovaza 4 
g/d + 
simvastati
n 
Placebo + 
simvastati
n 
17 
17 
60.1±2.7 12.0 2 
(1) 
Kowey, 
2010 
USA 
sPAF 
patient 
DB-RC
T 
Lovaza 4 
g/d 
Corn oil 
332 
331 
59.8±13.
4 
61.2±12.
3 
24.0 5 
(1) 
Maki, 2011 USA 
Dyslipide
mia 
patient 
DB-RC
T 
Lovaza 4 
g/d 
Corn oil 
19 
19 
56.4±2.7 6.0 3 
(1), (2) 
Ballantyne, 
2012 
USA 
Dyslipide
mia 
DB-RC
T 
Vascepa 4 
g/d 
233 
236 
61.1±10.
3 
12.0 4 (1), (3) 
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patient Vascepa 2 
g/d 
Placebo 
233 61.8±9.4 
61.1±10.
3 
Jacobson, 
2012 
USA 
Dyslipide
mia 
patient 
DB-RC
T 
Vascepa 4 
g/d 
Vascepa 
2g/d 
Placebo 
77 
76 
76 
51.9±10.
3 
53.4±9.3 
53.4±8.3 
12.0 3 
(1), (3) 
Tatsuno, 
2013  
(ORD) 
Japan 
Dyslipide
mia 
patient 
DB-RC
T 
TAK-085 2 
g/d 
TAK-085 4 
g/d 
EPA-E 1.8 
g/d 
206 
210 
195 
53.9±10.
8 
55.0±10.
5 
55.6±10.
5 
12.0 5 
(1), (2) 
Tatsuno, 
2013 
(ORL) 
Japan 
Dyslipide
mia 
patient 
SB-RC
T 
TAK-085 2 
g/d 
TAK-085 4 
g/d 
EPA-E 1.8 
g/d 
165 
171 
167 
56.0±11.
0 
55.9±10.
1 
55.8±10.
3 
52.0 2 
(1) 
de 
Ferranti, 
2014 
USA 
Dyslipide
mia 
patient 
DB-RC
T 
Lovaza 4 
g/d 
Corn oil 
12 
12 
13.3±2.4 
14.7±2.7 
24.0 5 
(2) 
Kastelein, 
2014 
USA 
Dyslipide
mia 
patient 
DB-RC
T 
Epanova 2 
g/d 
Epanova 3 
g/d 
Epanova 4 
g/d 
Corn oil 
100 
101 
99 
99 
51.1±9.8 
51.2±8.8 
52.9±10.
9 
50.8±10.
6 
12.0 5 
(1), (2), 
(3) 
Heydari,20
16 
USA 
AMI 
patient 
DB-RC
T 
Lovaza 4 
g/d 
Corn oil 
180 
178 
60.0±10.
0 
58.0±10.
0 
24.0 4 
(1), (2) 
 31 
Sandhu, 
2016 
USA 
PM 
healthy 
women 
SB-RC
T 
Lovaza 4 
g/d 
Lovaza 4 
g/d + 
raloxifene 
No 
treatment 
54 
53 
53 
56.6±6.9 
57.9±5.1 
57.1±5.9 
96.0 3 
(1), (2) 
Su, 2017 Taiwan 
Dyslipide
mia 
patient 
DB-RC
T 
Omacor 2 
g/d 
Omacor 4 
g/d 
Olive oil 
82 
84 
87 
54.7±9.2 
53.7±11.
0 
54.4±10.
7 
8.0 5 
(1), (2), 
(3) 
 
Extracted data*:(1) adverse events; (2) lipid profiles; (3) non-lipid laboratory measurements 
number of studies*: (1) =19; (2) =11; (3) =5 
Abbreviations: AMI: acute myocardial infarction; DHA, docosahexaenoic acid; DM: diabetes mellitus; EPA, 
eicosapentaenoid acid; HD: Huntington disease; ORD: omega-3 fatty acids randomized double-blind study; ORL: 
omega-3 fatty acids randomized long-term study; PTCA: percutaneous transluminal coronary angioplasty; PM: 
post-menopausal; RCT: randomized controlled trial; DB-RCT: double-blind randomized controlled trial; SB-RCT: 
single-blind randomized controlled trial; RxOM3FAs, prescription omega 3 fatty acids; sPAF: symptomatic 
paroxysmal atrial fibrillation; UK: the United Kingdom; USA: the United States of America. 
Table 2A: Meta-analysis of treatment-related adverse events 
 
Treatment-related adverse 
events 
Meta-analysis result Heterogeneity Publication bias 
SOC        Adverse 
events 
Dat
a 
OR 
95% 
CIs 
p 
Q 
valu
e 
d
f 
I
2
 
(%) 
p 
Significa
nce 
Adj. 
ES 
95% 
CIs 
Gastrointest
inal 
Disorders  
Abdominal 
pain 
3 
0.6
71 
0.23
0 to 
1.95
0.46
4 
0.62
5 
2 
<0.0
01 
0.7
32 
Sig. 
0.9
90 
0.42
2 to
 2.3
 32 
 3 24 
Constipation 3 
3.2
98 
0.63
8 to 
17.0
64 
0.15
5 
2.53
7 
2 
21.1
54 
0.2
81 
Sig. 
1.0
03 
0.15
7 to
 6.4
28 
Diarrhea 17 
1.2
14 
0.88
0 to 
1.67
4 
0.23
8 
18.8
33 
1
6 
15.0
43 
0.2
77 
n/s -- -- 
Dysgeusia 5 
4.2
29 
1.39
9 to 
12.7
80 
0.01
1 
0.11
7 
4 
<0.0
01 
0.9
98 
Sig. 
4.4
28 
1.55
6 to 
12.6
01 
Dyspepsia 6 
1.5
70 
0.59
9 to
 4.1
11 
0.35
9 
1.78
9 
5 
<0.0
01 
0.8
78 
Sig. 
1.1
72 
0.48
7 to
 2.8
23 
Eructation 6 
1.8
29 
0.57
1 to
 5.8
57 
0.30
9 
7.55
7 
5 
33.8
37 
0.1
82 
n/s -- -- 
Gastroesoph
ageal reflux 
6 
1.2
57 
0.52
7 to
 3.0
00 
0.60
6 
4.29
3 
5 
<0.0
01 
0.5
08 
Sig. 
0.9
58 
0.42
7 to
 2.1
45 
Nausea 13 
1.2
68 
0.80
4 to
 2.0
02 
0.30
7 
13.3
72 
1
2 
10.2
58 
0.3
43 
n/s -- -- 
abdominal 
pain, upper 
4 
1.3
70 
0.35
9 to
 5.2
22 
0.64
5 
1.82
8 
3 
<0.0
01 
0.6
09 
Sig. 
1.8
54 
0.53
9 to
 6.3
82 
Vomiting 4 
2.2
55 
0.60
7 to
 8.3
71 
0.22
4 
1.92
2 
3 
<0.0
01 
0.5
89 
n/s -- -- 
General Fatigue 3 3.6 0.58 0.16 0.07 2 <0.0 0.9 n/s -- -- 
 33 
Disorders 
and 
Administrati
on Site 
Conditions  
13 4 to
 22.
338 
7 2 01 65 
Musculoske
letal and 
Connective 
Tissue 
Disorders  
 
Arthralgia 8 
1.2
17 
0.66
7 to 
2.22
3 
0.52
2 
9.50
5 
7 
26.3
54 
0.2
18 
Sig. 
0.8
63 
0.44
2 to
 1.6
85 
Back pain 8 
0.6
84 
0.41
8 to 
1.12
1 
0.13
2 
2.92
2 
7 
<0.0
01 
0.8
92 
n/s -- -- 
Myalgia 8 
0.8
18 
0.66
3 to
 1.0
08 
0.06
0 
4.14
5 
7 
<0.0
01 
0.7
63 
Sig. 
0.8
23 
0.66
8 to
 1.0
15 
Infections 
and 
Infestations  
 
Bronchitis 4 
0.9
44 
0.49
8 to 
1.79
3 
0.86
1 
0.76
76 
3 
<0.0
01 
0.8
57 
Sig. 
0.8
79 
0.48
3 to
 1.6
01 
Gastroenterit
is 
4 
1.0
83 
0.45
4 to
 2.5
83 
0.85
7 
2.81
7 
3 
<0.0
01 
0.4
21 
Sig. 
0.7
88 
0.29
8 to
 2.0
86 
Influenza 6 
1.2
99 
0.66
8 to
 2.5
28 
0.44
1 
3.22
4 
5 
<0.0
01 
0.6
65 
Sig. 
1.1
25 
0.59
6 to
 2.1
26 
Nasopharyng
itis 
11 
0.9
48 
0.65
8 to
 1.3
67 
0.77
6 
16.0
21 
1
0 
37.5
82 
0.0
99 
n/s -- -- 
Pharyngitis 5 
0.7
56 
0.47
9 to
 1.1
93 
0.22
9 
2.87
7 
4 
<0.0
01 
0.5
79 
Sig. 
0.8
52 
0.55
5 to
 1.3
08 
Upper 8 1.0 0.70 0.91 5.89 7 <0.0 0.5 Sig. 1.0 0.72
 34 
respiratory 
tract 
infection 
20 6 to
 1.4
73 
6 6 01 52 45 6 to
 1.5
06 
Injury, 
poisoning 
and 
procedural 
complicatio
ns  
Contusion 3 
0.7
72 
0.32
4 to
 1.8
44 
0.56
1 
1.57
1 
2 
<0.0
01 
0.4
56 
n/s -- -- 
Nervous 
System 
Disorders  
Headache 7 
1.2
83 
0.52
1 to 
3.16
3 
0.58
8 
5.92
7 
6 
<0.0
01 
0.4
31 
Sig. 
1.0
60 
0.42
2 to 
2.66
1 
Skin and 
subcutaneo
us tissue 
disorders  
Rash 7 
2.4
61 
1.86
9 to
 3.2
42 
<0.0
01 
3.44
4 
6 
<0.0
01 
0.7
51 
Sig. 
2.4
19 
1.84
6 to
 3.1
70 
Cardiovascu
lar 
disorders 
Hypertension 3 
0.7
47 
0.20
9 to
 2.6
67 
0.65
3 
0.92
3 
2 
<0.0
01 
0.6
30 
n/s -- -- 
 
Abbreviation: adj. ES: Adjusted effect size; CI: confidence interval; n/s: not significant; OR: odds ratio; Sig.: 
significant 
SOC: System Organ Class 
Table 2B: Meta-analysis of treatment-related laboratory effects 
 
Treatment-related 
laboratory effects 
Meta-analysis result Heterogeneity Publication bias 
Dat
a 
Hedge
s’ g 
95% 
CIs 
p 
Q 
value 
df I
2
 (%) p 
Significan
ce 
Adj. 
ES 
95
% 
CIs 
Lipid 
profiles 
HDL 15 -0.077 
-0.20
4 to 
0.04
9 
0.232 
23.80
0 
1
4 
41.17
6 
0.048 n/s -- -- 
LDL 13 0.208 
0.05
2 to 
0.009 
28.79
5 
1
2 
58.32
6 
0.004 Sig. 
0.03
4 
-0.
14
 35 
0.36
4 
2 t
o 
0.2
11 
Non-HDL 7 -0.214 
-0.38
2 to
 -0.0
45 
0.013 
12.25
3 
6 
51.03
4 
0.057 Sig. 
-0.22
7 
-0.
39
1 t
o -
0.0
63 
T-Cho 12 -0.136 
-0.26
4 to
 -0.0
07 
0.039 
18.82
6 
1
1 
41.57
1 
0.064 n/s -- -- 
TG 11 -0.474 
-0.69
3 to
 -0.2
55 
<0.00
1 
47.20
3 
1
0 
78.81
5 
<0.00
1 
n/s -- -- 
VLDL 5 -0.499 
-0.85
6 to
 -0.1
43 
0.006 
26.18
0 
4 
84.72
1 
<0.00
1 
n/s -- -- 
Non-lip
id 
profiles 
AC sugar 8 0.121 
0.03
6 to 
0.20
6 
0.005 2.258 7 
<0.00
1 
0.944 n/s -- -- 
HbA1c 3 0.103 
-0.11
1 to 
0.31
8 
0.345 0.849 2 
<0.00
1 
0.654 n/s -- -- 
Uric acid 3 0.052 
-0.14
9 to
 0.2
54 
0.610 0.453 2 
<0.00
1 
0.797 Sig. 
0.06
8 
-0.
12
2 t
o 
0.2
59 
Albumin 3 -0.105 
-0.31
2 to
0.317 3.231 2 
38.10
7 
0.199 n/s -- -- 
 36 
 0.1
01 
ALP 5 -0.206 
-0.33
5 to 
-0.07
6 
0.002 3.897 4 
<0.00
1 
0.420 Sig. 
-0.23
2 
-0.
35
1 t
o -
0.1
12 
ALT 8 0.099 
0.01
4 to 
0.18
4 
0.022 1.701 7 
<0.00
1 
0.975 n/s -- -- 
Apo-B 3 -0.058 
-0.24
9 to
 0.1
34 
0.554 4.816 2 
58.46
8 
0.090 n/s -- -- 
AST 8 0.040 
-0.04
4 to 
0.12
5 
0.352 3.719 7 
<0.00
1 
0.811 Sig. 
0.06
8 
-0.
01
0 t
o 
0.1
46 
Bicarbona
te 
3 -0.154 
-0.31
6 to
 0.0
09 
0.064 0.617 2 
<0.00
1 
0.734 n/s -- -- 
BUN 5 0.132 
0.00
2 to
 0.2
63 
0.047 4.060 4 1.488 0.398 n/s -- -- 
Ca 3 0.081 
-0.08
2 to
 0.2
43 
0.329 1.892 2 
<0.00
1 
0.388 n/s -- -- 
CK 5 0.050 
-0.11
4 to
 0.2
15 
0.547 
10.93
7 
4 
63.42
9 
0.027 Sig. 
-0.06
8 
-0.
25
3 t
o 
 37 
0.1
16 
Cl 5 0.001 
-0.12
9 to
 0.1
30 
0.992 0.371 4 
<0.00
1 
0.985 Sig. 
0.01
0 
-0.
10
7 t
o 
0.1
28 
Cre 8 0.024 
-0.06
1 to
 0.1
08 
0.585 5.948 7 
<0.00
1 
0.546 Sig. 
0.06
4 
-0.
00
8 t
o 
0.1
36 
K 5 -0.036 
-0.22
6 to
 0.1
54 
0.712 8.471 4 
52.78
1 
0.076 Sig. 
-0.12
9 
-0.
31
2 t
o 
0.0
53 
Na 5 0.037 
-0.09
2 to
 0.1
67 
0.573 3.749 4 
<0.00
1 
0.441 n/s -- -- 
P 3 0.000 
-0.16
2 to
 0.1
62 
1.000 
<0.00
1 
2 
<0.00
1 
1.000 n/s -- -- 
T-Bil 5 -0.062 
-0.19
1 to
 0.0
68 
0.349 1.803 4 
<0.00
1 
0.772 Sig. 
-0.07
8 
-0.
19
6 t
o 
0.0
39 
Total 
protein 
5 0.050 
-0.09
7 to
 0.1
96 
0.506 5.112 4 
21.75
6 
0.276 n/s -- -- 
 38 
Hb 6 0.204 
0.07
5 to 
0.33
4 
0.002 2.921 5 
<0.00
1 
0.712 n/s -- -- 
Hct 6 0.173 
0.04
3 to
 0.3
02 
0.009 1.810 5 
<0.00
1 
0.875 Sig. 
0.11
6 
0.0
06
 to
 0.
22
6 
Plt 6 -0.170 
-0.29
9 to
 -0.0
41 
0.010 4.278 5 
<0.00
1 
0.510 Sig. 
-0.21
5 
-0.
33
1 t
o -
0.1
00 
WBC 5 0.014 
-0.11
8 to
 0.1
47 
0.833 0.461 4 
<0.00
1 
0.977 n/s -- -- 
 
Abbreviation: adj. ES: Adjusted effect size; CI: confidence interval; n/s: not significant; Sig.: significant 
 
Table 3A: Subgroup analysis of treatment-related adverse events 
Treatment-related adverse events 
Meta-analysis result 
Data 
Odds 
ratio 
95% CI p Data 
Odds 
ratio 
95% CI p 
SOC            Adverse events 
Combination products (EPA+DHA) EPA-only products 
Gastrointestinal 
Disorders 
Abdominal pain 3 0.671 
0.230 to 
1.953 
0.464 n/d n/d n/d n/d 
Constipation 3 3.298 
0.638 to 
17.064 
0.155 n/d n/d n/d n/d 
Diarrhea 12 1.408 
0.940 to 
2.109 
0.096 5 0.932 
0.557 to 
1.561 
0.789 
Dysgeusia 5 4.229 
1.399 to 
12.780 
0.011 n/d n/d n/d n/d 
Dyspepsia 6 1.570 0.599 to 0.359 n/d n/d n/d n/d 
 39 
4.111 
Eructation 4 4.247 
1.411 to 
12.779 
0.010 n/d n/d n/d n/d 
Gastroesophageal 
reflux 
6 1.257 
0.527 to 
3.000 
0.606 n/d n/d n/d n/d 
Nausea 9 1.730 
1.014 to 
2.950 
0.044 4 0.732 
0.375 to
 1.430 
0.361 
Upper abdominal 
pain 
4 1.370 
0.359 to 
5.222 
0.645 n/d n/d n/d n/d 
Vomit 4 2.255 
0.607 to 
8.371 
0.224 n/d n/d n/d n/d 
General 
Disorders and 
Administration 
Site Conditions 
Fatigue 3 3.613 
0.584 to 
22.338 
0.167 n/d n/d n/d n/d 
Musculoskeletal 
and Connective 
Tissue 
Disorders 
Arthralgia 5 1.137 
0.483 to 
2.678 
0.768 3 2.238 
0.443 to 
11.295 
0.329 
Back pain 8 0.684 
0.418 to 
1.121 
0.132 n/d n/d n/d n/d 
Myalgia 7 1.033 
0.535 to 
1.993 
0.924 n/d n/d n/d n/d 
Infections and 
Infestations 
Bronchitis 4 0.944 
0.498 to 
1.793 
0.861 n/d n/d n/d n/d 
Gastroenteritis 4 1.083 
0.454 to 
2.583 
0.857 n/d n/d n/d n/d 
Influenza 5 1.148 
0.496 to 
2.656 
0.747 n/d n/d n/d n/d 
Nasopharyngitis 8 1.078 
0.727 to 
1.598 
0.710 3 0.589 
0.284 to
 1.222 
0.155 
Pharyngitis 5 0.756 
0.479 to 
1.193 
0.229 n/d n/d n/d n/d 
Upper respiratory 
tract infection 
8 1.020 
0.706 to 
1.473 
0.916 n/d n/d n/d n/d 
Injury, 
poisoning and 
procedural 
complications 
Contusion n/d n/d n/d n/d n/d n/d n/d n/d 
Nervous System Headache 7 1.283 0.521 to 0.588 n/d n/d n/d n/d 
 40 
Disorders 3.163 
Skin and 
subcutaneous 
tissue disorders 
Skin rash 6 2.248 
0.922 to 
5.482 
0.075 n/d n/d n/d n/d 
Cardiovascular 
disorders 
Hypertension 3 0.747 
0.209 to 
2.667 
0.653 n/d n/d n/d n/d 
Abbreviation: CI: confidence interval; n/d: not done 
Table 3B: Subgroup analysis of treatment-related laboratory effects 
 
Treatment-related 
laboratory effects 
Meta-analysis result 
Data 
Hedges’ 
g 
95% CI p Data 
Hedges’ 
g 
95% CI p 
Combination products (EPA+DHA) EPA-only products 
Lipid 
profiles 
HDL 15 -0.077 
-0.204 to 
0.049 
0.232 n/d n/d n/d n/d 
LDL 13 0.208 
0.052 to 
0.364 
0.009 n/d n/d n/d n/d 
Non-HDL 7 -0.214 
-0.382 to -
0.045 
0.013 n/d n/d n/d n/d 
T-Cho 12 -0.136 
-0.264 to -
0.007 
0.039 n/d n/d n/d n/d 
TG 11 -0.474 
-0.693 to -
0.255 
<0.001 n/d n/d n/d n/d 
VLDL 5 -0.499 
-0.856 to -
0.143 
0.006 n/d n/d n/d n/d 
Non-lipid 
profiles 
AC sugar 6 0.123 
-0.003 to 
0.249 
0.057 n/d n/d n/d n/d 
HbA1c n/d n/d n/d n/d n/d n/d n/d n/d 
Uric acid 3 0.052 
-0.149 to 
0.254 
0.610 n/d n/d n/d n/d 
Albumin 3 -0.105 
-0.312 to 
0.101 
0.317 n/d n/d n/d n/d 
ALP 5 -0.206 
-0.335 to 
-0.076 
0.002 n/d n/d n/d n/d 
ALT 6 0.104 
-0.022 to 
0.231 
0.105 n/d n/d n/d n/d 
Apo-B 3 -0.058 -0.249 to 0.554 n/d n/d n/d n/d 
 41 
0.134 
AST 6 -0.016 
-0.142 to 
0.110 
0.803 n/d n/d n/d n/d 
Bicarbonate 3 -0.154 
-0.316 to 
0.009 
0.064 n/d n/d n/d n/d 
BUN 5 0.132 
0.002 to 0.
263 
0.047 n/d n/d n/d n/d 
Ca 3 0.081 
-0.082 to 
0.243 
0.329 n/d n/d n/d n/d 
CK 3 0.200 
0.037 to 0.
362 
0.016 n/d n/d n/d n/d 
Cl 5 0.001 
-0.129 to 
0.130 
0.992 n/d n/d n/d n/d 
Cre 6 0.083 
-0.043 to 
0.209 
0.197 n/d n/d n/d n/d 
K 5 -0.036 
-0.226 to 
0.154 
0.712 n/d n/d n/d n/d 
Na 5 0.037 
-0.092 to 
0.167 
0.573 n/d n/d n/d n/d 
P 3 0.000 
-0.162 to 
0.162 
1.000 n/d n/d n/d n/d 
T-Bil 5 -0.062 
-0.191 to 
0.068 
0.349 n/d n/d n/d n/d 
Total 
protein 
5 0.050 
-0.097 to 
0.196 
0.506 n/d n/d n/d n/d 
Hb 6 0.204 
0.075 to 
0.334 
0.002 n/d n/d n/d n/d 
Hct 6 0.173 
0.043 to 0.
302 
0.009 n/d n/d n/d n/d 
Plt 6 -0.170 
-0.299 to -
0.041 
0.010 n/d n/d n/d n/d 
WBC 5 0.014 
-0.118 to 
0.147 
0.833 n/d n/d n/d n/d 
 
Abbreviation: CI: confidence interval; n/d: not done 
Highlights 
 Among the 21 included RCTs, there was no definite evidence of any 
 42 
RxOME3FA-emerging serious adverse event. 
 RxOME3FAs were associated with more treatment-related dysgeusia (fishy taste) and 
skin abnormalities (eruption, itching, exanthema, or eczema). Besides, RxOME3FAs 
had mild adverse effects upon some non-lipid laboratory measurements. 
 EPA/DHA combination products were associated with more treatment-related 
gastrointestinal adverse events [eructation (belching); nausea] and mild elevation of 
low-density lipoprotein cholesterol. 
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